| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6b482e14e97aaf93ee35b6ccc3daf9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8e71233d46c313ac971fc4f9e4aa4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85465399e60c80e7fe42026c69a8d3f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6bbef6685885d5a435a144f79c450e10 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6837
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2003-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1553c424a56bea5340108316018d7c80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9a44cda9d663878c42edaebfc511ae2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_813507d645459ed019abfb0335539f17 |
| publicationDate |
2004-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004006753-A2 |
| titleOfInvention |
Sga-72m, a cancer associated antigen, and uses thereof |
| abstract |
The present invention relates to a gene and gene product, SGA-72M that is differentially expressed in cancer tissues and cell-lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-72M in cancer tissues and cell-lines. Northern blot analysis and semi-quantitative RTÂPCR demonstrated over expression of SGA-72M in breast cancer tissue and breast cancer derived cell-lines. The gene is expressed as a 4.2kb mRNA. The SGA-72M cDNA comprises an open reading frame encoding 1342 amino acids. Monitoring expression levels of SGA-72M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Antagonists that inhibit SGA-72M expression or activity are useful for the treatment of cancer. The SGA-72M polypeptide is associated with the plasma membrane and is on the cell surface of breast carcinoma cells and is a useful target for antibody-based therapeutics. |
| priorityDate |
2002-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |